Y.H. Park

Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study

Peter Schmid, Roberto Salgado, Y.H. Park et al. · Annals of Oncology · 2020 · 423 citations

Phase 1B, Breast Oncology, Oncology +9

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated ( gBRCA m) platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Yvette Drew, Maja J.A. de Jonge, Sook Hee Hong et al. · Gynecologic Oncology · 2018 · 130 citations

Gbrca M, Medicine, Gynecology +6

VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC

Peter Schmid, Javier Cortés, Rebecca Dent et al. · Annals of Oncology · 2021 · 130 citations · Full text

Medicine, Adjuvant Pembrolizumab, Immunology +9

LBA21 KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer

Fátima Cardoso, Heather L. McArthur, Peter Schmid et al. · Annals of Oncology · 2023 · 128 citations · Full text

Breast Oncology, Oncology, Lba21 Keynote-756 +9

Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522

Lajos Pusztai, Carsten Denkert, Joyce O’Shaughnessy et al. · Annals of Oncology · 2024 · 123 citations · Full text

Medicine, Immunology, Pathology +7